司库奇尤单抗治疗与银屑病、银屑病关节炎或强直性脊柱炎患者结核再激活的关联
5年观察期内,13例(0.1%)报告LTBI不良事件,无活动性结核病例,LTBI报告不常见。
要点
- 研究中未报告活动性结核病例。
- 结果支持在慢性系统性炎症性疾病中使用司库奇尤单抗。
核心结论
- 司库奇尤单抗治疗后LTBI报告为不良事件不常见,未报告活动性结核病例,结果支持其用于慢性系统性炎症性疾病。
研究设计与样本
- 汇总队列研究,整合28项司库奇尤单抗临床试验数据(银屑病17项3期或3b期及2项4期,银屑病关节炎5项3期,强直性脊柱炎4项3期)。
主要发现
- 5年内13例(0.1%)报告LTBI不良事件,其中6例既往LTBI检测阳性,7例新诊断LTBI。
- 7例新诊断LTBI中,4例银屑病(EAIR 0.03,95%CI 0.01-0.07)、1例银屑病关节炎(EAIR 0.02,95%CI 0.00-0.11)、2例强直性脊柱炎(EAIR 0.08,95%CI 0.01-0.28)。
- 未报告活动性结核病例。
临床怎么用
- 司库奇尤单抗治疗中LTBI报告率低,支持在筛查和按指南处理LTBI后用于慢性系统性炎症性疾病。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
IMPORTANCE: Approximately one-quarter of the global population have latent tuberculosis infection (LTBI), and tuberculosis (TB) is accountable for more than 1.5 million deaths annually. Methotrexate, cyclosporine, and tumor necrosis factor inhibitors may be associated with increased risk of TB and LTBI reactivation, although data are limited on the risks of TB with use of newer biologics. OBJECTIVE: To assess the association of secukinumab with reporting of active TB development, TB reactivation, and LTBI activation as an adverse event (AE) in patients with psoriasis, psoriatic arthritis, or ankylosing spondylitis. DESIGN, SETTING, AND PARTICIPANTS: This pooled cohort study pooled data from 28 clinical trials of secukinumab used in psoriasis (17 phase 3 or 3b and 2 phase 4 trials), psoriatic arthritis (5 phase 3 trials), and ankylosing spondylitis (4 phase 3 trials). A search of the Novartis Secukinumab Compound Pool Database was conducted for the 28 trials. All trial participants who had received at least 1 approved subcutaneous dose of secukinumab (150 mg or 300 mg) were included. Before randomization in these trials, patients underwent screening for TB. Patients with active TB were excluded, and patients with LTBI were treated according to local guidelines. Data were analyzed from the start of treatment in the individual studies through December 25, 2018. MAIN OUTCOMES AND MEASURES: Reporting of active TB or LTBI as an AE over a 5-year period using exposure-adjusted incidence rates (EAIR; incidence rates per 100 patient-years). RESULTS: A total of 12 319 patients were included, of whom 8819 patients had psoriasis (71.6%; 5930 men [67.2%]; mean [SD] age, of 44.9 [13.5] years), 2523 had psoriatic arthritis (20.5%; 1323 women [52.4%]; mean [SD] age, 48.8 [12.1] years), and 977 had ankylosing spondylitis (7.3%; 658 men [67.3%]; mean [SD] age, 42.3 [11.9] years). In the total population, 684 patients (5.6%) had tested positive for LTBI at screening. Over 5 years, LTBI as an AE during secukinumab treatment was reported in 13 patients (0.1% of 12 319). Of these 13 patients, 6 had a prior positive LTBI test result, and 7 were newly diagnosed as having LTBI. Four of the 7 patients had psoriasis (EAIR, 0.03; 95% CI, 0.01-0.07), 1 had psoriatic arthritis (EAIR, 0.02; 95% CI, 0.00-0.11), and 2 had ankylosing spondylitis (EAIR, 0.08; 95% CI, 0.01-0.28). No cases of active TB were reported. CONCLUSIONS AND RELEVANCE: This study found that LTBI reported as an AE after secukinumab treatment was uncommon and appeared to support the use of secukinumab in chronic systemic inflammatory conditions.
引用
- Elewski BE, Baddley JW, Deodhar AA, et al. Association of Secukinumab Treatment With Tuberculosis Reactivation in Patients With Psoriasis, Psoriatic Arthritis, or Ankylosing Spondylitis. JAMA Dermatol. 2021. PMID: 33001147. doi:10.1001/jamadermatol.2020.3257
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。